Salud
Novartis signs license deal worth up to $2.9 billion for PTC Therapeutics drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics promising an experimental drug to treat a neurological disorder called Huntington’s disease, sending
Argentine HIV patients and medical professionals fear the impact of Milei’s spending cuts
Argentines living with HIV/AIDS and medical professionals say spending cuts under libertarian President Javier Milei are hurting treatment for the disease and could lead to
New Zealand suspends poultry exports after first case of H7 avian influenza
New Zealand said on Monday it had suspended all poultry exports following the detection of a highly pathogenic variant of avian influenza at a South
The U.S. Supreme Court will review the FDA’s denial of registration of flavored vape products
The U.S. Supreme Court on Monday will consider the U.S. Food and Drug Administration’s defence of the agency’s refusal to allow two e-cigarette companies to
British lawmakers give their backing to assisted dying bill
The British Parliament backed a new bill to allow assisted dying. 330 lawmakers voted for and 275 against the ‘Terminally Ill Adults’ bill, which would
The Mpox outbreak could reach a plateau next year
The number of mpox cases will continue to rise over the next four weeks before showing signs of stabilizing early next year, the African Centers
New case of mpox variant of the Ib clade discovered in England
The UK Health Safety Agency (UKHSA) said on Friday that another case of the new mpox strain of clade Ib has been identified in England.
Amgen’s anti-obesity drug reduces weight by up to 20%
Amgen’s experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average, according to a year-long mid-stage trial. The data fell
Musk’s Neuralink will begin feasibility trials with a brain implant and robotic arm
Elon Musk’s brain research startup Neuralink said Monday it has received approval to launch a new feasibility study using its brain implant and experimental robotic
Roche records failure in Phase III study of two lung cancer drugs
Roche’s Phase III study of using the combination of tiragolumab and tecentriq to treat a form of lung cancer did not achieve the desired success,